6/17
02:05 pm
gpcr
Structure Therapeutics Inc. (NASDAQ: GPCR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.
Low
Report
Structure Therapeutics Inc. (NASDAQ: GPCR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.
6/17
01:30 pm
gpcr
Rating for GPCR
Low
Report
Rating for GPCR
6/7
10:37 am
gpcr
Rating for GPCR
Low
Report
Rating for GPCR
6/7
10:37 am
gpcr
Rating for GPCR
Low
Report
Rating for GPCR
6/3
11:06 am
gpcr
Structure Therapeutics Inc. (NASDAQ: GPCR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.
Medium
Report
Structure Therapeutics Inc. (NASDAQ: GPCR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.
6/3
10:47 am
gpcr
Rating for GPCR
High
Report
Rating for GPCR
5/21
08:42 am
gpcr
Rating for GPCR
Low
Report
Rating for GPCR
5/21
07:35 am
gpcr
Structure Therapeutics Inc. (NASDAQ: GPCR) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $65.00 price target on the stock.
Low
Report
Structure Therapeutics Inc. (NASDAQ: GPCR) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $65.00 price target on the stock.
5/10
01:37 pm
gpcr
Structure Therapeutics Inc. (NASDAQ: GPCR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $91.00 price target on the stock.
Medium
Report
Structure Therapeutics Inc. (NASDAQ: GPCR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $91.00 price target on the stock.
5/10
01:37 pm
gpcr
Structure Therapeutics Inc. (NASDAQ: GPCR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $91.00 price target on the stock.
Medium
Report
Structure Therapeutics Inc. (NASDAQ: GPCR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $91.00 price target on the stock.
5/10
12:49 pm
gpcr
Rating for GPCR
Medium
Report
Rating for GPCR
5/10
12:49 pm
gpcr
Rating for GPCR
Medium
Report
Rating for GPCR
5/3
01:34 pm
gpcr
Structure Therapeutics Inc. (NASDAQ: GPCR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.
Low
Report
Structure Therapeutics Inc. (NASDAQ: GPCR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.
5/3
11:20 am
gpcr
Rating for GPCR
Low
Report
Rating for GPCR
4/18
10:22 am
gpcr
Structure Therapeutics Inc. (NASDAQ: GPCR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.
Low
Report
Structure Therapeutics Inc. (NASDAQ: GPCR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.
4/18
09:51 am
gpcr
Rating for GPCR
Low
Report
Rating for GPCR
4/9
08:09 am
gpcr
Structure Therapeutics Inc. (NASDAQ: GPCR) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $65.00 price target on the stock.
Low
Report
Structure Therapeutics Inc. (NASDAQ: GPCR) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $65.00 price target on the stock.
4/9
07:02 am
gpcr
Rating for GPCR
Medium
Report
Rating for GPCR
4/9
06:16 am
gpcr
Structure Therapeutics initiated with bullish view at Cantor Fitzgerald
Medium
Report
Structure Therapeutics initiated with bullish view at Cantor Fitzgerald